CU24515B1 - Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio - Google Patents
Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodioInfo
- Publication number
- CU24515B1 CU24515B1 CU2016000048A CU20160048A CU24515B1 CU 24515 B1 CU24515 B1 CU 24515B1 CU 2016000048 A CU2016000048 A CU 2016000048A CU 20160048 A CU20160048 A CU 20160048A CU 24515 B1 CU24515 B1 CU 24515B1
- Authority
- CU
- Cuba
- Prior art keywords
- sodium
- pyrimidin
- olate
- dosage forms
- pharmaceutical dosage
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940074045 glyceryl distearate Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 1
- VYRQLKYGGSWDNH-UHFFFAOYSA-M sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate Chemical compound [Na+].[O-]C1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1 VYRQLKYGGSWDNH-UHFFFAOYSA-M 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se relaciona con formas sólidas de dosificación farmacéutica para administración oral que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio (ingrediente activo (I), de la fórmula:</p> <p>ESPACIO PARA FÓRMULA I</p> <p>caracterizadas porque el ingrediente activo (I) contiene del 10 al 40 % de la masa total de la formulación, y como excipientes: hidroxipropilmetilcelulosa (HPMC), celulosa microcristalina o manitol, croscarmelosa de sodio, estearil fumarato de sodio o glicerildiestearato.</p> <p>Estas formas sólidas son útiles como medicamentos en la profilaxis secundaria o el tratamiento de trastornos, particularmente trastornos cardiovasculares, fallo cardíaco, anemia, trastornos renales crónicos e insuficiencia renal. </p> <p> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189145 | 2013-10-17 | ||
| PCT/EP2014/071855 WO2015055564A1 (de) | 2013-10-17 | 2014-10-13 | Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160048A7 CU20160048A7 (es) | 2016-10-28 |
| CU24515B1 true CU24515B1 (es) | 2021-05-12 |
Family
ID=49356354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000048A CU24515B1 (es) | 2013-10-17 | 2014-10-13 | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9827198B2 (es) |
| EP (1) | EP3057580B1 (es) |
| JP (1) | JP6525979B2 (es) |
| KR (1) | KR102330953B1 (es) |
| CN (1) | CN105636580B (es) |
| AP (1) | AP2016009135A0 (es) |
| AR (1) | AR098064A1 (es) |
| AU (1) | AU2014336389B2 (es) |
| BR (1) | BR112016007588A2 (es) |
| CA (1) | CA2927437C (es) |
| CL (1) | CL2016000857A1 (es) |
| CU (1) | CU24515B1 (es) |
| DK (1) | DK3057580T3 (es) |
| DO (1) | DOP2016000078A (es) |
| EA (1) | EA032932B1 (es) |
| ES (1) | ES2868228T3 (es) |
| GT (1) | GT201600072A (es) |
| HR (1) | HRP20210691T1 (es) |
| HU (1) | HUE054107T2 (es) |
| IL (1) | IL244933B (es) |
| JO (1) | JO3645B1 (es) |
| LT (1) | LT3057580T (es) |
| MA (1) | MA38974B2 (es) |
| MX (1) | MX2016004628A (es) |
| MY (1) | MY190202A (es) |
| NI (1) | NI201600054A (es) |
| PE (1) | PE20160669A1 (es) |
| PH (1) | PH12016500716A1 (es) |
| SA (1) | SA516370940B1 (es) |
| SI (1) | SI3057580T1 (es) |
| TN (1) | TN2016000135A1 (es) |
| TW (1) | TWI746418B (es) |
| UA (1) | UA119855C2 (es) |
| UY (1) | UY35784A (es) |
| WO (1) | WO2015055564A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210346392A1 (en) * | 2018-08-31 | 2021-11-11 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| WO2008120548A2 (ja) * | 2007-03-13 | 2008-10-09 | Dainippon Sumitomo Pharma Co., Ltd. | 口腔内崩壊錠 |
| DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2014
- 2014-10-13 US US15/029,215 patent/US9827198B2/en active Active
- 2014-10-13 HU HUE14783642A patent/HUE054107T2/hu unknown
- 2014-10-13 HR HRP20210691TT patent/HRP20210691T1/hr unknown
- 2014-10-13 LT LTEP14783642.3T patent/LT3057580T/lt unknown
- 2014-10-13 WO PCT/EP2014/071855 patent/WO2015055564A1/de not_active Ceased
- 2014-10-13 AU AU2014336389A patent/AU2014336389B2/en not_active Ceased
- 2014-10-13 AP AP2016009135A patent/AP2016009135A0/en unknown
- 2014-10-13 KR KR1020167009621A patent/KR102330953B1/ko not_active Expired - Fee Related
- 2014-10-13 MA MA38974A patent/MA38974B2/fr unknown
- 2014-10-13 MX MX2016004628A patent/MX2016004628A/es unknown
- 2014-10-13 CA CA2927437A patent/CA2927437C/en active Active
- 2014-10-13 EP EP14783642.3A patent/EP3057580B1/de active Active
- 2014-10-13 EA EA201690788A patent/EA032932B1/ru not_active IP Right Cessation
- 2014-10-13 PE PE2016000498A patent/PE20160669A1/es unknown
- 2014-10-13 CN CN201480056547.1A patent/CN105636580B/zh not_active Expired - Fee Related
- 2014-10-13 BR BR112016007588A patent/BR112016007588A2/pt not_active Application Discontinuation
- 2014-10-13 CU CU2016000048A patent/CU24515B1/es unknown
- 2014-10-13 UA UAA201605150A patent/UA119855C2/uk unknown
- 2014-10-13 TN TN2016000135A patent/TN2016000135A1/en unknown
- 2014-10-13 MY MYPI2016701355A patent/MY190202A/en unknown
- 2014-10-13 ES ES14783642T patent/ES2868228T3/es active Active
- 2014-10-13 JP JP2016523207A patent/JP6525979B2/ja active Active
- 2014-10-13 DK DK14783642.3T patent/DK3057580T3/da active
- 2014-10-13 SI SI201431801T patent/SI3057580T1/sl unknown
- 2014-10-15 UY UY0001035784A patent/UY35784A/es not_active Application Discontinuation
- 2014-10-15 TW TW103135607A patent/TWI746418B/zh not_active IP Right Cessation
- 2014-10-16 JO JOP/2014/0295A patent/JO3645B1/ar active
- 2014-10-17 AR ARP140103868A patent/AR098064A1/es unknown
-
2016
- 2016-04-04 IL IL244933A patent/IL244933B/en active IP Right Grant
- 2016-04-08 DO DO2016000078A patent/DOP2016000078A/es unknown
- 2016-04-12 CL CL2016000857A patent/CL2016000857A1/es unknown
- 2016-04-14 NI NI201600054A patent/NI201600054A/es unknown
- 2016-04-14 GT GT201600072A patent/GT201600072A/es unknown
- 2016-04-14 SA SA516370940A patent/SA516370940B1/ar unknown
- 2016-04-15 PH PH12016500716A patent/PH12016500716A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200222A1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| PH12020550341A1 (en) | Niraparib formulations | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| CR20110704A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica | |
| EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| CU24515B1 (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio | |
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| BR112016015175A2 (pt) | Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido | |
| MX2016001155A (es) | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion. | |
| WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
| CR20160177A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio | |
| MX2017012999A (es) | Acido pirrolidona carboxilico (pca) para uso oftalmico. | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| RU2013127881A (ru) | Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения | |
| EA201992816A1 (ru) | Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения | |
| RU2013157796A (ru) | Фармацевтическая композиция на основе моксифлоксацина | |
| UA97982U (uk) | Лікарський засіб седативної дії у вигляді таблеток |